-
The Benchmark Company Sees Xenotis Acquisition As Good For LeMaitre Vascular
Tuesday, August 19, 2014 - 9:57am | 139In a report published Tuesday, The Benchmark Company analyst Jan Wald reiterated a Buy rating and $11.00 price target on LeMaitre Vascular (NASDAQ: LMAT). In the report, The Benchmark Company noted, “LeMaitre Vascular, a Buy rated stock with an $11 price target announced the acquisition today,...
-
Wall Street Comfortable With Covidien Buy; Some See Move By Johnson & Johnson
Monday, June 16, 2014 - 4:29pm | 421Wall Street appeared comfortable with the latest big healthcare merger, this one the acquisition of Covidien (NYSE: COV) by Medtronic (NYSE: MDT), a deal which turns eyes to Johnson & Johnson (NYSE: JNJ). "We expect many investors will expect J&J to buy something in the cardiac...
-
UPDATE: Benchmark Initiates On Covidien On Diversification Based Growth
Thursday, December 5, 2013 - 8:02am | 194In a report published Thursday, Benchmark analyst Jan Wald initiated a Buy rating on Covidien (NYSE: COV) and initiated a price target of $82.00. In the report, Benchmark says "We are initiating coverage of Covidien with a Buy rating and an $82 price target. Covidien differs from many companies in...
-
UPDATE: Benchmark Company Initiates Coverage on LeMaitre Vascular on Multiple Positive Factors
Thursday, October 24, 2013 - 10:35am | 170In a report published Thursday, Benchmark Company analyst Jan Wald initiated coverage on LeMaitre Vascular (NASDAQ: LMAT) with a Buy rating and $9.00 price target. In the report, Benchmark Company noted, “We are initiating coverage on LeMaitre Vascular with a Buy rating and a $9 price target. We...
-
UPDATE: Benchmark Initiates Coverage on Insulet Corporation Following Strong Response to New OmniPod
Tuesday, October 15, 2013 - 11:30am | 145In a report published Tuesday, Benchmark Company analyst Jan Wald initiated coverage on Insulet Corporation (NASDAQ: PODD) with a Buy rating and $44.00 price target. In the report, Benchmark Company noted, “We are initiating coverage of Insulet with a Buy rating and $44 price target. Our view is...
-
UPDATE: Benchmark Initiates Coverage on DexCom on Upside From New G4 Platinum Sensor
Tuesday, October 15, 2013 - 11:30am | 148In a report published Tuesday, Benchmark Company analyst Jan Wald initiated coverage on DexCom (NASDAQ: DXCM) with a Buy rating and $37.00 price target. In the report, Benchmark Company noted, “We are initiating coverage of Dexcom with a Buy rating and a $37 price target, supported by the upside...
-
UPDATE: Benchmark Initiates Coverage on Abiomed on Potential of Impella Device
Tuesday, October 1, 2013 - 8:57am | 188In a report published Tuesday, Benchmark Company analyst Jan Wald initiated coverage on Abiomed (NASDAQ: ABMD) with a Speculative Buy rating and $25.00 price target. In the report, Benchmark Company noted, “We are initiating coverage of Abiomed with a Speculative Buy rating and Price Target of $25...
-
UPDATE: Benchmark Initiates Coverage on Sunshine Heart on Potential of C-Pulse Heart Assist System
Tuesday, October 1, 2013 - 8:57am | 202In a report published Tuesday, Benchmark Company analyst Jan Wald initiated coverage on Sunshine Heart (NASDAQ: SSH) with a Speculative Buy rating and $16.00 price target. In the report, Benchmark Company noted, “We are initiating coverage of Sunshine Heart with a Speculative Buy rating and Price...